Abstract
Identification of the underlying genetic causes of single gene disorders of the arteries has led to improved understanding of the aberrant signalling pathways involved and is producing disease-specific medical therapies beyond simple control of blood pressure and heart rate. Here, Baderkhan et al. report their experience with celiprolol treatment in 40 patients with mutations in the gene COL3A1 causing vascular Ehlers-Danlos Syndrome (vEDS). The dose of celiprolol was up-titrated every six months to reach 400 mg daily, and was well tolerated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Vascular & Endovascular Surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
